New CAR t therapy aims to tackle tough multiple myeloma
NCT ID NCT07421856
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 participants to check safety and how well the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SENL103 autologous BCMA-targeting CAR T cells
What this could lead to
If successful, this could offer a new treatment option for patients with multiple myeloma that has come back or not responded to other therapies.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••